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Objectives. This study was undertaken to identify a South
African mineral water containing relatively high
concentrations of calcium and magnesium and to
investigate its effect on urinary biochemical and
physicochemical risk factors associated with calcium
oxalate kidney stone formation.
Design. The study followed a change-over design in
which each subject followed a randomised sequence of
three water-drinking protocols involving their normal diet,
a calcium and magnesium-rich mineral water and a
mineral water deficient in these elements.
Setting. University of Cape Town.
Subjects. 54 volunteers without any previous history of
stone disease (27 men, 27 women) in the age group 21 -
35 years and 31 with a history of calcium oxalate kidney
stones (24 men, 7 women) in the age group 25 - 45 years
participated in the study.
Outcome measures. Both mineral waters favourably
altered several risk factors. However, the effect of the
calcium- and magnesium-rich water was shown to be
significantly greater as it altered a larger number of these
factors and induced several unique changes that were not
achieved by the other water.
Conclusions. The risk of calcium oxalate stone formation
can be significantly reduced by consumption of mineral
water which is rich in calcium and magnesium.
S Afr Med J 1998; 88: 448-451.
In a recent study, the risk of calcium oxalate (CaOx) stone
formation was shown to decrease significantly after
consumption of a French mineral water. 1 The prophylactic
effect of the water was attributed to its high calcium and
magnesium content as it has recently been proposed that
calcium binds free oxalate in the gut, thereby reducing the
amount of the latter which is absorbed; this reduces its
concentration in the urine and thus reduces the risk of CaOx
urolithiasis 2 On the other hand, magnesium has been
recognised as an inhibitor of CaOx stone formation for many
years by virtue of its ability to form soluble magnesium
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oxalate which is excreted harmlessly in the urine.' The
present study was undertaken to identify a South African
mineral water containing levels of calcium and magnesium
similar to those in the French water and to investigate
whether it, too, would reduce the risk of CaOx kidney stone
formation.
Subjects and methods
Six commercially available South African mineral waters
(Baden, Caledon, Ceres, LaVie, Schoonspruit and Valpre)
were randomly selected for analysis. The magnesium and
calcium concentrations in each water were measured with a
Varian 1275 Model flame atomic absorption spectrometer.
Fifty-four subjects with no previous history of stone
disease (27 men, 27 women) in the age group 21 - 35 years
and 31 with a history of CaOx stone formation (24 men, 7
women) in the age group 25 - 45 years participated in the
study. All of the latter had suffered a stone episode in the
month prior to participation in the project; confirmation of
stone type was achieved by X-ray powder diffraction.
Subjects were required to supply a 24-hour urine sample
while on their free unrestricted diets as well as after two
drinking protocols involving a mineral water with a high
magnesium and calcium content and one containing
relatively low concentrations of these two components. In
each of the water-drinking protocols, 1.5 litres per day were
consumed for a period of 3 days. Urine was collected during
the final 24 hours. Glass bottles (2.5 litres), which had been
thoroughly washed with 5M hydrochloric acid and rinsed
with distilled water, were used for this purpose. No
preservative was present. During the collection period the
bottle and contents were refrigerated.
Urines were tested for the presence of blood and infection
(Combur 10 test strip; Boehringer Mannheim). Samples in
which haematuria was detected or which were found to be
nitrite-positive were discarded. Thereafter, volume and pH
were recorded. Urines were analysed for sodium, potassium,
calcium and magnesium content by means of flame atomic
absorption spectrometry. Oxalate content was determined
with oxalate decarboxylase. For these analyses an ascorbate
oxidase spatula was used to remove L-ascorbic acid. Citrate
content was determined by citrate lyase conversions to
oxalo-acetate. Inorganic phosphorus level was determined
with ammonium molybdate; creatinine content was
determined with picric acid and uric acid level was
determined with uricase. Analytical kits manufactured by
Boehringer Mannheim were used for these determinations.
The metastable limit (MSL) of urine is a measure of how
readily it supports crystallisation! The method for its
determination has been described elsewhere.' Briefly,
successive aliquots of aqueous sodium oxalate (NaOx) are
added in progressively increasing concentrations to the
urine, until CaOx crystallisation (as detected by turbidity
measurements) is initiated. The concentration of exogenous
NaOx required to produce detectable crystallisation is taken
as the MSL. It follows that an increase in the MSL (e.g. after
administration of a therapeutic protocol) corresponds to a
decrease in the likelihood of stone formation.
Several physicochemical quotients, ratios and indices,
which have been empirically derived and which have been
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Table I. Biochemical and physicochemical risk factors determined
in the urine of all subjects in this study
Statistical design and analysis
The study was statistically planned to follow a Latin square
cross-over design9 in which each subject participated in a
randomised sequence of the three protocols (i.e. normal
diet, calcium- and magnesium-rich water, calcium- and
widely used by stone researchers in assessing the efficacy
of treatment regimens, were determined prior to and after
the water-drinking protocols. Among the most important of
these were the CaOx relative supersaturation," the 'risk
index" and the standardised activity product.s All
incorporate urinary component concentrations in
mathematical functions, the output of which (in each case) is
a number which indicates the potential for stone formation.
The higher the relative value of the number, the higher the
risk. Risk index and activity product values for all urines
were calculated by means of the published equations,"s
while relative supersaturation values were determined with
the speciation computer program, EQUIL.s A summary of the
biochemical and physicochemical risk factors which were





The concentrations of magnesium and calcium of six
randomly selected South African mineral waters are
presented in the histogram in Fig. 1. On the basis of these
results, Schoonspruit (calcium- and magnesium-rich) and
Caledon (calcium- and magnesium-deficient) mineral waters
were selected for the trial. Tables 11 - V give those risk
factors for each of the four groups in which a statistically
significant change occurred (relative to normal diet values)
as a result of either the Schoonspruit or Caledon protocols,
or both. In this table a 't' symbol indicates a favourable
change (i.e. a shift towards lower stone risk). An asterisk W
indicates that the effect of one protocol was more significant
than that of the other. Risk factors which were measured,
but which did not change significantly in any group, were pH
and calcium, sodium, potassium, uric acid and phosphate
excretions. However, because pH is an important indicator
of urine milieu, mean values are included in Tables 11 - V.
Fig. 1. Mg and Ca concentrations (mg/l) in 6 randomly selected




magnesium-deficient water). The data were analysed by the
method of analysis of variance; comparisons between
protocols were made with Student's t-test to establish which
of a multitude of risk factors might change significantly. All






















Table 11. Male controls (N = 27) - mean risk factor values associated with each protocol, standard errors and pairwise P comparisons
Drinking protocol Pairwise P-values
Normal (N) Caledon (C) Schoonspruit (S) N v. C N v. S Cv. S
MSL 0.53 (0.08r 0.69 (0.08) 0.75 (0.08) 0.15 0.04 0.58
Risk index 318 (30) 284 (29) 174 (30) 0.40 < 0.01 t 0.01
CaOx RS 4.96 (0.36) 3.52 (0.34) 2.10 (0.35) < 0.01t < 0.01t· < 0.01
Brush RS 1.35 (0.14) 0.93 (0.14) 1.04 (0.14) 0.04t 0.12 0.57
UARS 2.11 (0.24) 1.20 (0.24) 1.15 (0.24) 0.011 0.011 0.88
Vol (cm') 1 537 (116) 2203 (116) 1 973 (116) < 0.01t 0.C1t 0.16
Cit (mmol/24 h) 2.18 (0.22) 2.83 (0.22) 2.82 (0.22) 0.04t 0.04t 0.97
Ox (mmol/24 h) 0.29 (0.01) 0.30 (0.01) 0.17 (0.01) 0.61 < 0.01t < 0.01
APS 1.32 (0.10) 1.28 (0.10) 0.78 (0.10) 0.79 < 0.01t < 0.01
pH 6.00 (0.08) 6.21 (0.08) 6.23 (0.08) 0.07 0.05 0.90
• More signifrcant effect of one protOCOl relative to the other.
t Favourable change in the risk factor.
MSL ; metastable limit (M NaOx); CaOx RS ; calcium oxalate relative supersaturation; Brush RS ; brushite relative supersaturation; UA RS ; uric acid relative supetSaturation;
APS ; standardised CaOx activity product.
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Table Ill. Men with stone formation (N =24) - mean risk factor values associated with each protocol, standard errors and pairwise P
comparisons
Drinking protocol Pairwise P-values
Normal (N) Caledon (C) Schoonspruit (S) N v. C N v. S Cv. S
Risk index 405 (32) 269 (32) 229 (32) < a.on < 0.01t 0.37
CaOx RS 6.26 (0.39) 3.63 (0.38) 3.53 (0.37) < 0.01t < 0.01t 0.85
Vol (cm') 1 359 (126) 1 877 (126) 1 829 (126) < 0.01t o.on 0.79
Cit (mmoV24 h) 2.11 (0.24) 2.72 (0.24) 2.95 (0.24) 0.07 0.01t 0.51
Ox (mmol/24 h) 0.32 (0.02) 0.26 (0.02) 0.20 (0.02) < 0.01t < o.on· 0.01
Mg (mmol/24 h) 3.35 (0.31) 4.03 (0.31) 4.38 (0.31) 0.12 0.02t 0.42
APS 1.52 (0.11) 1.33 (0.11) 1.03 (0.11) 0.21 < 0.01t 0.05
pH 5.96 (0.09) 5.96 (0.09) 5.98 (0.09) 0.99 0.91 0.92
• More significant effect of one protocol relative to the other.
t Favourable change in the risk factor.
CaOx RS = calcium oxalate relative supersaturation; APS = standardised CaOx activity product.
Table IV. Female controls (N =27) - mean risk factor values associated with each protocol, standard errors and pairwise P comparisons
Drinking protocol Pairwise P-values
Normal (N) Caledon (C) Schoonspruit (S) N v. C N v. S Cv. S
Risk index 352 (29) 367 (29) 216 (29) 0.72 < 0.01t < 0.01
CaOx RS 3.49 (0.35) 2.64 (0.34) 1.57 (0.34) 0.08 < 0.01t 0.03
Vol (cm') 1 504 (116) 2342 (114) 2257 (116) < 0.01t < 0.01t 0.60
Cit (mmol/24 h) 2.73 (0.22) 3.32 (0.22) 3.47 (0.22) 0.06 0.02t 0.63
Ox (mmoV24 h) 0.23 (0.01) 0.25 (0.01) 0.15 (0.01) 0.44 < 0.01t < 0.01
APS 0.91 (0.10) 1.07 (0.10) 0.60 (0.10) 0.25 0.03t < 0.01
pH 6.20 (0.08) 6.23 (0.08) 6.32 (0.08) 0.77 0.29 0.44
t Indicates a favourable change in the risk factor.
CaOx RS = calcium oxalate relative supersaturation; APS ~ standardised CaOx activity product.
Table V. Women with stone formation (N =7) - mean risk factor values associated with each protocol, standard errors and pairwise P
comparisons
Drinking protocol Pairwise P-values
Normal (N) Caledon (C) Schoonspruit (S) N v. C N v. S Cv. S
Risk index 409 (63) 325 (63) 215 (63) 0.32 0.02t 0.19
CaOx RS 4.62 (0.72) 3.96 (0.72) 2.36 (0.72) 0.50 0.02t 0.10
Ox (mmol/24 h) 0.26 (0.03) 0.24 (0.03) 0.15 (0.03) 0.72 0.01t 0.02
pH 6.20 (0.08) 6.23 (0.08) 6.32 (0.08) 0.77 0.29 0.44
t Indicates a favourable change in the risk factor.
CaOx AS =calcium oxalate re1ative supersaturation.
Discussion
80th protocols indu.ced several favourable changes in the
urinary risk factors. However, the number of factors altered
by the Schoonspruit protocol was greater than that affected
by the Caledon protocol. Furthermore, when both protocols
altered the same risk factor, the effect of Schoonspruit was
more significant in two of these - CaOx relative
supersaturation (Table 11) and oxalate excretion (Table Ill). It
is also noteworthy that Caledon had no effect on the risk
factors in women with a history of stone disease, while
Schoonspruit altered three of them (Table V).
Three risk factors were favourably altered in all four
groups: oxalate excretion, CaOx relative supersaturation and
the CaOx 'risk index'. Of these, oxalate excretion is Widely
regarded as the most crucial determinant in CaOx
_urolithiasis." The results show that Schoonspruit uniquely
achieved a decrease in this risk factor in male controls,
female controls and women with a history of stone
formation; in men who had experienced stone formation the
desired decrease was achieved by both waters, but
Schoonspruit was significantly more effective. The CaOx
relative supersaturation and the CaOx risk index decreased
in the four groups after consumption of Schoonspruit, Le.
favourable shifts occurred in all eight risk factors while a
similar effect occurred in only three of these factors after
consumption of Caledon. It should be noted that one of the
other risk quotients determined in this study - the
standardised CaOx activity product - decreased
significantly in male and female controls as well as in men
who had experienced stone formation, after the
Schoonspruit protocol. In women who had had kidney
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stones, the decreasing trend was evident but not significant
(P = 0.0708). The standardised activity product was not
affected in any group by the Caledon protocol.
Also worthy of comment is the significant increase in
citrate excretion in three groups after mineral water
consumption (Tables \I - IV) while in the fourth group (women
who had experienced stone formation) an increasing (but not
significant) trend occurred (normal: 2.08 (0.47); Caledon:
1.99 (0.47); Schoonspruit: 2.74 (0.47)). These observations
are of great importance as they provide further evidence in
support of the risk-reducing effect of mineral water.
However, it is intriguing that the increased citrate excretion
was not accompanied by increasing pH values. The
mechanism by which this could have occurred is unknown.
The results of this study have demonstrated that both
Schoonspruit and Caledon mineral water favourably altered
several biochemical and physicochemical risk factors related
to CaOx kidney stone formation. However, the effect of
Schoonspruit was shown to be significantly greater, as it
altered a larger number of risk factors and induced several
unique changes in key determinants which were not
achieved by the Caledon protocol. Since the two waters
differ markedly in respect of their calcium and magnesium
content (Fig. 1), it is suggested that these components
afford Schoonspruit mineral water its inhibitory capacity in
respect of stone formation. This result supports the
hypothesis that delivery of a large fluid volume containing
relatively high levels of calcium and magnesium reduces the
risk of stone development.' Therefore, mineral waters such
as Schoonspruit, which satisfy this criterion, can be
effectively recommended as a therapeutic protocol in CaOx
kidney stone disease.
The author wishes to thank the Medical Research Council, the
Foundation for Research and Development and the University of
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Do stroke patients realise
that a consequence of
hypertension is stroke?
L A Hale, V U Fritz, C J Eales
Study objective. The specific objectives of the study were
to survey residual disability and handicap following stroke.
Information on four risk factors, namely hypertension, age,
smoking, and alcohol abuse, was obtained. Enquiry was
made into the subjects' insight into the causes of their
problems.
Design. Descriptive survey.
Setting. Baragwanath Hospital and Soweto.
Participants. Stroke patients 12 - 14 weeks post-
discharge.
Outcome measures. Structured questionnaire.
Results. A total of 361 patients were initially screened.
Only 54 fulfilled all inclusion criteria, 38 (70%) over 50
years of age and 16 (30%) under 50 years. Ninety-three of
the 361 died within the first 3 months; 71 % of all patients
knew that they had suffered a stroke. Only 20% of the
total group understood that hypertension had probably
caused their stroke, although 76% of the older group and
56% ef the younger group had been told at some stage
that they were hypertensive. Of the older group 32% knew
the name of their medication, 21 % could not name their
medication and 23% claimed they were on no medication.
Similarly in the younger group, 19% could name their
medication, 25% could not name their medication, and
12% were on no medication. In addition, 16% ofthe older
group and 56% of the younger group admitted to
smoking. The abuse of alcohol in both groups was low,
but this figure was taken from subjective assessment and
may not reflect the true extent of drinking as a risk factor.
Conclusion. Most patients in this study appear well
aware of their hypertension and take medication. However,
they seem unaware that their hypertension and stroke are
causally linked and their hypertension knowledge is
suboptimal. It is also apparent that smoking is increasing
as a major risk factor for stroke in the black population of
South Africa. Patients need more education regarding
hypertension and its consequences.
S Air Med J 1998; 88: 451-454.
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